Tu SM - Search Results

1

Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Navone NM, et al. Among authors: tu sm. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500. Clin Cancer Res. 1997. PMID: 9815652

2

Effect of Paget's disease of bone (osteitis deformans) on the progression of prostate cancer bone metastasis.

Tu SM, Som A, Tu B, Logothetis CJ, Lee MH, Yeung SC. Tu SM, et al. Among authors: tu b. Br J Cancer. 2012 Aug 7;107(4):646-51. doi: 10.1038/bjc.2012.315. Epub 2012 Jul 17. Br J Cancer. 2012. PMID: 22805323 Free PMC article.

3

Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. McDonnell TJ, et al. Among authors: tu sm. Cancer Res. 1992 Dec 15;52(24):6940-4. Cancer Res. 1992. PMID: 1458483

4

Phase I study of suramin combined with doxorubicin in the treatment of androgen-independent prostate cancer.

Tu SM, Pagliaro LC, Banks ME, Amato RJ, Millikan RE, Bugazia NA, Madden T, Newman RA, Logothetis CJ. Tu SM, et al. Clin Cancer Res. 1998 May;4(5):1193-201. Clin Cancer Res. 1998. PMID: 9607577 Clinical Trial.

5

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.

Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ. Ellerhorst JA, et al. Among authors: tu sm. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2371-6. Clin Cancer Res. 1997. PMID: 9815636 Clinical Trial.

6

A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.

Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. Lin SH, et al. Among authors: tu sm. Oncogene. 2008 Sep 4;27(39):5195-203. doi: 10.1038/onc.2008.156. Epub 2008 May 19. Oncogene. 2008. PMID: 18490922 Free PMC article.

7

Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.

Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Som A, et al. Among authors: tu sm. Br J Cancer. 2012 Oct 23;107(9):1547-53. doi: 10.1038/bjc.2012.436. Epub 2012 Oct 2. Br J Cancer. 2012. PMID: 23033003 Free PMC article.

8

Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.

Tu SM, McConnell K, Marin MC, Campbell ML, Fernandez A, von Eschenbach AC, McDonnell TJ. Tu SM, et al. Cancer Lett. 1995 Jul 13;93(2):147-55. doi: 10.1016/0304-3835(95)03795-x. Cancer Lett. 1995. PMID: 7621422

9

Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo.

Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC, McDonnell TJ. Beham AW, et al. Among authors: tu sm. Int J Mol Med. 1998 Jun;1(6):953-9. doi: 10.3892/ijmm.1.6.953. Int J Mol Med. 1998. PMID: 9852630

10

A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma.

Pagliaro L, Daliani D, Amato R, Tu SM, Jones D, Smith T, Logothetis C, Millikan R. Pagliaro L, et al. Among authors: tu sm. Cancer. 2000 Aug 1;89(3):615-8. Cancer. 2000. PMID: 10931461 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

196 results

Search Page

Filters